Clinical Complete Response of Aggressive Fibromatosis to Apatinib and Celecoxib: A Case Report

Han T1#, Lv CX2#, Cui JJ1, Zhuo M1, Liu TF1, Lin XL1* and Xiao XY1*

1Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China
2Department of Oncology, Punan Hospital of Pudong New District, Shanghai, China
#These authors contributed equally to this work

^*Correspondance to: Xiu-Ying Xiao 

 PDF  Full Text Case Report | Open Access

Abstract:

Aggressive Fibromatosis (AF) is a rare disease that originates from fibroblasts in deep soft tissues. Surgery and radiotherapy are the main treatment options, while there is still controversial with systematic treatment for patients who cannot undergo surgery or radiotherapy. Here, we reported a case of a 53-year-old Chinese woman with gastric cancer combined with aggressive fibromatosis. She was firstly diagnosed early gastric cancer, which was curative by surgery. While, a solid mass located in the epigastric region was detected at a follow-up examination after 2 years. Then, puncture biopsy of abdominal mass was conducted, and subsequent histopathology confirmed aggressive fibromatosis. The patient received apatinib combined with celecoxib. Amazingly, the tumor was regressed remarkably, and achieved clinical Complete Response (cCR). In conclusion, apatinib combined with celecoxib was an effective and safe treatment strategy for aggressive fibromatosis.

Keywords:

Aggressive fibromatosis; Apatinib; Celecoxib; cCR: Gastric Cancer

Cite the Article:

Han T, Lv CX, Cui JJ, Zhuo M, Liu TF, Lin XL, et al. Clinical Complete Response of Aggressive Fibromatosis to Apatinib and Celecoxib: A Case Report. Ann Clin Case Rep. 2024; 9: 2614..